

 KENTUCKY YMCA YOUTH ASSOCIATION KENTUCKY YOUTH ASSEMBLY Commonwealth Bill	Blue CW 16						
	Referred to Committee: House 2						
Authors: Nick Koenig	Action on the Bill <table> <tr> <td>House</td> <td>Senate</td> </tr> <tr> <td>___ <input type="checkbox"/> Passed</td> <td>___ <input type="checkbox"/> Passed</td> </tr> <tr> <td>___ <input type="checkbox"/> Defeated</td> <td>___ <input type="checkbox"/> Defeated</td> </tr> </table>	House	Senate	___ <input type="checkbox"/> Passed	___ <input type="checkbox"/> Passed	___ <input type="checkbox"/> Defeated	___ <input type="checkbox"/> Defeated
House		Senate					
___ <input type="checkbox"/> Passed		___ <input type="checkbox"/> Passed					
___ <input type="checkbox"/> Defeated	___ <input type="checkbox"/> Defeated						
School: duPont Manual HS							
City: Louisville							

1 An act to expand terminally ill patients’ access to experimental drugs, biological products, and devices
2
3 **Be it enacted by the Youth Assembly of the Commonwealth of Kentucky**
4
5 Section 1: Also known as the Right to Try, this bill will authorize access to and use of experimental
6 treatments for patients with a terminal illness; to establish conditions for use of experimental
7 treatment; to prohibit sanctions of health care providers solely for recommending or providing
8 experimental treatment; to clarify duties of a health insurer with regard to experimental treatment
9 authorized under this act; to prohibit certain actions by state officials, employees, and agents; and to
10 restrict certain causes of action arising from experimental treatment.
11
12 Section 2: These experimental drugs, biological products, and/or devices must (at least) complete phase
13 one of the Food & Drug Administration’s (FDA) clinical trial, that is a test for toxicity.
14
15 Section 3: The bill will be enacted January 1st, 2016.
16
17 Section 4: This act does not expand the coverage required of an insurer. A health plan, third party
18 administrator, or governmental agency may, but is not required to, provide coverage for the cost of an
19 investigational drug, biological product, or device, or the cost of services related to the use of an
20 investigational drug, biological product, or device under this act.
21
22 Section 5: This act does not require any governmental agency to pay costs associated with the use,
23 care, or treatment of a patient with an investigational drug, biological product, or device. This act does
24 not require a licensed hospital or facility to provide new or additional services, unless approved by the
25 hospital or facility.